Published clinical studies on DNMT3A mutations
. | Ley3 . | Thol9 . | Ribeiro1 . | Patel5 . | Shen10 . | Hou8 . | Marcucci6 . | Renneville7 . |
---|---|---|---|---|---|---|---|---|
Patients analyzed (N) | 281 | 489 | 415 | 398 | 1141 | 500 | 415 | 123 |
DNMT3A mut (N) | 62 | 87 | 96 | 89 | 75 | 70 | 148 | 36 |
DNMT3A mut (%) | 22 | 18 | 23 | 22 | 7 | 14 | 36 | 29 |
AML population (all adult) | all | < 60/de novo | < 60 | < 60 | de novo | de novo | CN/de novo | CN, < 60/de novo |
DNMT3A region analyzed | complete | E15–23 | E11–23 | complete | complete | E2–23 | E15–23 | E8–9/E11–23 |
Median age, y (mut/wt) | 53/48* | 52/45*** | 51/41*** | ng | 54/38*** | 61/49*** | 61/62 | 48/47 |
Median WBC (Gpt/l) (mut/wt) | 59/39*** | 38/17** | 53/23*** | ng | 38/7*** | 32/16*** | 43/22*** | 13/11 |
Median BM blasts (%) (mut/wt) | 70/70 | 78/70* | 68/68 | ng | 78/65*** | ng | 58/57 | ng |
FAB | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 |
Median CR rate (%) (mut/wt) | ng | 71/76 | 89/79 | ng | 46/62* | ns | ns | 90/80 |
Median OS (mo mut/wt) | 12/41*** | 21/40* | 12/24 | 14/21 | P < .001 | 15/38 | P = .07 | 23/45* |
Median DFS/RFS (mo mut/wt) | ng | P = .2 | ng | ng | P < .001 | 8/15 | P = .03 | ng |
CN-AML (%) | 72*** | 82*** | 75*** | ng | ng | 51 | only CN | only CN |
NPM1 mut (%)† | 60 | 64 | 76 | 64 | 54 | 75* | 67 | |
FLT3-ITD (%)† | 41 | 39 | 41 | ng | 43 | 44* | 19 | |
CEBPA mut (%)† | ng | ng | 3 | 7 | 4 | 5*** | 0 | |
MLL-PTD (%)† | ng | ng | ng | 6 | 9 | 6 | ng | |
TET2 mut (%)† | ng | ng | ng | 7 | 9 | 22 | ng |
. | Ley3 . | Thol9 . | Ribeiro1 . | Patel5 . | Shen10 . | Hou8 . | Marcucci6 . | Renneville7 . |
---|---|---|---|---|---|---|---|---|
Patients analyzed (N) | 281 | 489 | 415 | 398 | 1141 | 500 | 415 | 123 |
DNMT3A mut (N) | 62 | 87 | 96 | 89 | 75 | 70 | 148 | 36 |
DNMT3A mut (%) | 22 | 18 | 23 | 22 | 7 | 14 | 36 | 29 |
AML population (all adult) | all | < 60/de novo | < 60 | < 60 | de novo | de novo | CN/de novo | CN, < 60/de novo |
DNMT3A region analyzed | complete | E15–23 | E11–23 | complete | complete | E2–23 | E15–23 | E8–9/E11–23 |
Median age, y (mut/wt) | 53/48* | 52/45*** | 51/41*** | ng | 54/38*** | 61/49*** | 61/62 | 48/47 |
Median WBC (Gpt/l) (mut/wt) | 59/39*** | 38/17** | 53/23*** | ng | 38/7*** | 32/16*** | 43/22*** | 13/11 |
Median BM blasts (%) (mut/wt) | 70/70 | 78/70* | 68/68 | ng | 78/65*** | ng | 58/57 | ng |
FAB | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 | M4/M5 |
Median CR rate (%) (mut/wt) | ng | 71/76 | 89/79 | ng | 46/62* | ns | ns | 90/80 |
Median OS (mo mut/wt) | 12/41*** | 21/40* | 12/24 | 14/21 | P < .001 | 15/38 | P = .07 | 23/45* |
Median DFS/RFS (mo mut/wt) | ng | P = .2 | ng | ng | P < .001 | 8/15 | P = .03 | ng |
CN-AML (%) | 72*** | 82*** | 75*** | ng | ng | 51 | only CN | only CN |
NPM1 mut (%)† | 60 | 64 | 76 | 64 | 54 | 75* | 67 | |
FLT3-ITD (%)† | 41 | 39 | 41 | ng | 43 | 44* | 19 | |
CEBPA mut (%)† | ng | ng | 3 | 7 | 4 | 5*** | 0 | |
MLL-PTD (%)† | ng | ng | ng | 6 | 9 | 6 | ng | |
TET2 mut (%)† | ng | ng | ng | 7 | 9 | 22 | ng |